Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Related Citations for PubMed (Select 23266540)

1.

Angiotensin II, independent of plasma renin activity, contributes to the hypertension of autonomic failure.

Arnold AC, Okamoto LE, Gamboa A, Shibao C, Raj SR, Robertson D, Biaggioni I.

Hypertension. 2013 Mar;61(3):701-6. doi: 10.1161/HYPERTENSIONAHA.111.00377. Epub 2012 Dec 24.

2.
3.

Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients.

Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, et al.

Hypertension. 1995 Jan;25(1):37-46.

4.

Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.

Goldberg MR, Tanaka W, Barchowsky A, Bradstreet TE, McCrea J, Lo MW, McWilliams EJ Jr, Bjornsson TD.

Hypertension. 1993 May;21(5):704-13.

5.

Long-term effects of telmisartan on blood pressure, the renin-angiotensin-aldosterone system, and lipids in hypertensive patients.

Aoki A, Ogawa T, Sumino H, Kumakura H, Takayama Y, Ichikawa S, Nitta K.

Heart Vessels. 2010 May;25(3):195-202. doi: 10.1007/s00380-009-1186-6. Epub 2010 May 29.

PMID:
20512446
6.

Effects of losartan on the renin-angiotensin-aldosterone axis in essential hypertension.

Bauer IH, Reams GP, Wu Z, Lau-Sieckman A.

J Hum Hypertens. 1995 Apr;9(4):237-43.

PMID:
7595905
7.
8.
9.

Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats.

Varagic J, Ahmad S, VonCannon JL, Moniwa N, Brosnihan KB, Wysocki J, Batlle D, Ferrario CM.

Am J Hypertens. 2013 May;26(5):583-90. doi: 10.1093/ajh/hps090. Epub 2013 Mar 4.

11.
12.

Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats.

Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Chappell MC, Ferrario CM.

Am J Physiol Heart Circ Physiol. 2006 Nov;291(5):H2166-72. Epub 2006 Jun 9.

13.
14.

Protective effects of the angiotensin II type 1 (AT1) receptor blockade in low-renin deoxycorticosterone acetate (DOCA)-treated spontaneously hypertensive rats.

Chamorro V, Wangensteen R, Sainz J, Duarte J, O'Valle F, Osuna A, Vargas F.

Clin Sci (Lond). 2004 Mar;106(3):251-9.

16.

Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.

Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, Marion R, Pecker MS, Sotelo J, August P, Pickering TG, Laragh JH.

Am J Hypertens. 1999 May;12(5):451-9.

PMID:
10342782
17.
18.

[Differences of blood plasma renin activity, angiotensin II and aldosterone levels in essential or secondary hypertension].

Song AL, Zeng ZP, Tong AL, Lu L, Chen S, Li M, Fu CL, Wang YH, Sun ML.

Zhonghua Nei Ke Za Zhi. 2012 Apr;51(4):294-8. Chinese.

PMID:
22781950
19.

Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension.

van den Meiracker AH, Admiraal PJ, Derkx FH, Kleinbloesem C, Man in 't Veld AJ, van Brummelen P, Mulder P, Schalekamp MA.

J Hypertens. 1993 Aug;11(8):831-8.

PMID:
8228207
20.

Captopril in primary hypertension. Effects related to the renin-angiotensin-aldosterone and kallikrein-kinin systems.

Ohman KP, Karlberg BE, Nilsson OR, Wettre S.

Acta Med Scand Suppl. 1981;646:98-105.

PMID:
7018190
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk